drugset / Trial / NCT05369039

Roflumilust in Chronic Rhinosinusitis With Nasal Polyposis.

NCT05369039

Phase 2 Unknown 60 enrolled Menoufia University
RandomizedParallel-groupSingle-blindTreatment

Summary

The current study will be a pilot study for a randomized controlled trial conducted on 60 patients recruited from the outpatient clinic of the Otorhinolaryngology Department, Menoufia Faculty of Medicine after approval of the institutional review board and taking informed written consent from every patient before participation in the study. The patients of this study will be randomly and equally distributed among case and control groups to compare the effect of Roflumilust administration with the effect of systemic and local corticosteroids on patients with chronic rhinosinusitis with nasal polyposis

Timeline

Start
2022-06
Primary completion
2023-03
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisolone Other / unclassified 40 mg Oral
Subject Roflumilust Unknown 500 mg